IRIS Accounts Production v26.1.10.61 14217383 Board of Directors 1.4.25 31.3.26 31.3.26 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh142173832025-03-31142173832026-03-31142173832025-04-012026-03-31142173832024-03-31142173832024-04-012025-03-31142173832025-03-3114217383ns15:EnglandWales2025-04-012026-03-3114217383ns14:PoundSterling2025-04-012026-03-3114217383ns10:Director12025-04-012026-03-3114217383ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3114217383ns10:SmallEntities2025-04-012026-03-3114217383ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3114217383ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3114217383ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3114217383ns10:FullAccounts2025-04-012026-03-311421738312025-04-012026-03-3114217383ns10:Director22025-04-012026-03-3114217383ns10:Director32025-04-012026-03-3114217383ns10:RegisteredOffice2025-04-012026-03-3114217383ns5:CurrentFinancialInstruments2026-03-3114217383ns5:CurrentFinancialInstruments2025-03-3114217383ns5:ShareCapital2026-03-3114217383ns5:ShareCapital2025-03-3114217383ns5:RetainedEarningsAccumulatedLosses2026-03-3114217383ns5:RetainedEarningsAccumulatedLosses2025-03-3114217383ns5:NetGoodwill2025-04-012026-03-3114217383ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3114217383ns5:ComputerSoftware2025-04-012026-03-3114217383ns5:LongLeaseholdAssetsns5:LandBuildings2025-04-012026-03-3114217383ns5:PlantMachinery2025-04-012026-03-3114217383ns5:FurnitureFittings2025-04-012026-03-3114217383ns5:ComputerEquipment2025-04-012026-03-3114217383ns5:NetGoodwill2025-03-3114217383ns5:ComputerSoftware2025-03-3114217383ns5:NetGoodwill2026-03-3114217383ns5:ComputerSoftware2026-03-3114217383ns5:NetGoodwill2025-03-3114217383ns5:ComputerSoftware2025-03-3114217383ns5:LongLeaseholdAssetsns5:LandBuildings2025-03-3114217383ns5:PlantMachinery2025-03-3114217383ns5:FurnitureFittings2025-03-3114217383ns5:ComputerEquipment2025-03-3114217383ns5:LongLeaseholdAssetsns5:LandBuildings2026-03-3114217383ns5:PlantMachinery2026-03-3114217383ns5:FurnitureFittings2026-03-3114217383ns5:ComputerEquipment2026-03-3114217383ns5:LongLeaseholdAssetsns5:LandBuildings2025-03-3114217383ns5:PlantMachinery2025-03-3114217383ns5:FurnitureFittings2025-03-3114217383ns5:ComputerEquipment2025-03-3114217383ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3114217383ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-31
REGISTERED NUMBER: 14217383 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026

FOR

LAKEWOOD PHARMACY LIMITED

LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


LAKEWOOD PHARMACY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2026







DIRECTORS: K M Chung
C H A Lam
D Tanna





REGISTERED OFFICE: 114-116 Goodmayes Road
Goodmayes
Essex
IG3 9UZ





REGISTERED NUMBER: 14217383 (England and Wales)





ACCOUNTANTS: Ashfords Partnership LLP
114 - 116 Goodmayes Road
Ilford
Essex
IG3 9UZ

LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

BALANCE SHEET
31 MARCH 2026

31.3.26 31.3.25
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 190,251 206,648
Tangible assets 5 31,114 36,033
221,365 242,681

CURRENT ASSETS
Stocks 6 90,114 80,139
Debtors 7 127,591 113,546
Cash at bank and in hand 187,840 186,441
405,545 380,126
CREDITORS
Amounts falling due within one year 8 494,802 503,478
NET CURRENT LIABILITIES (89,257 ) (123,352 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

132,108

119,329

PROVISIONS FOR LIABILITIES 11,305 10,293
NET ASSETS 120,803 109,036

CAPITAL AND RESERVES
Called up share capital 1 1
Retained earnings 120,802 109,035
120,803 109,036

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

BALANCE SHEET - continued
31 MARCH 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 2 October 2026 and were signed on its behalf by:





K M Chung - Director


LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026


1. STATUTORY INFORMATION

Lakewood Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2023, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Computer software is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Long leasehold - in accordance with the property
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 25% on reducing balance
Computer equipment - 33% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Operating leases
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The accounts have been prepared on a going concern basis on the assumption that the Company will continue to receive adequate financial assistance from its directors.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2025 - 6 ) .

4. INTANGIBLE FIXED ASSETS
Computer
Goodwill software Totals
£    £    £   
COST
At 1 April 2025 250,772 10,667 261,439
Additions - 10,830 10,830
At 31 March 2026 250,772 21,497 272,269
AMORTISATION
At 1 April 2025 54,754 37 54,791
Amortisation for year 25,077 2,150 27,227
At 31 March 2026 79,831 2,187 82,018
NET BOOK VALUE
At 31 March 2026 170,941 19,310 190,251
At 31 March 2025 196,018 10,630 206,648

LAKEWOOD PHARMACY LIMITED (REGISTERED NUMBER: 14217383)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026


5. TANGIBLE FIXED ASSETS
Fixtures
Long Plant and and Computer
leasehold machinery fittings equipment Totals
£    £    £    £    £   
COST
At 1 April 2025 21,210 2,000 16,562 6,607 46,379
Additions - 3,390 - 6,221 9,611
At 31 March 2026 21,210 5,390 16,562 12,828 55,990
DEPRECIATION
At 1 April 2025 3,966 918 2,103 3,359 10,346
Charge for year 6,672 1,118 3,615 3,125 14,530
At 31 March 2026 10,638 2,036 5,718 6,484 24,876
NET BOOK VALUE
At 31 March 2026 10,572 3,354 10,844 6,344 31,114
At 31 March 2025 17,244 1,082 14,459 3,248 36,033

6. STOCKS
31.3.26 31.3.25
£    £   
Stocks 90,114 80,139

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade debtors 60,468 50,321
Other debtors 67,123 63,225
127,591 113,546

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade creditors 139,328 151,693
Amounts owed to group undertakings 322,406 327,071
Taxation and social security 13,662 17,848
Other creditors 19,406 6,866
494,802 503,478

9. ULTIMATE CONTROLLING PARTY

The company is controlled by the parent company, Ammonite Pharmaceuticals Limited.